TSE:5201Building
AGC (TSE:5201) Valuation Check as AGC Biologics Expands CDMO Capabilities with ATUM Partnership
AGC (TSE:5201) just gave investors a fresh reason to revisit the story, with AGC Biologics partnering with ATUM to bring the Leap In Transposase platform into its global cell line development offering.
See our latest analysis for AGC.
That backdrop of governance reshuffles and strategic partnerships seems to be landing well with investors, with a roughly 10 percent 3 month share price return and a solid multi year total shareholder return suggesting that momentum is gradually building.
If...